Rx Medicare

DNA vaccination using lupus autoantigens and interleukin-10 (IL-10, a cytokine that plays an important role in regulating the immune system) has potential as a novel therapy to induce antigen specific tolerance and may help to prevent kidney damage in patients with systemic lupus erythematosus, according to a new study.

Read More…

Related Posts

• Anxiety And Depression Lower Quality Of Life In Majority Of Systemic Lupus Erythematosus Patients
• Novel Intranasal Nanoemulsion Vaccine Adjuvant Also Effective By Subcutaneous And Intramuscular Injection
• Immune Responses To Flu Vaccine Are Diminished In Lupus Patients
• VaxInnate Reports Positive Results From Preclinical Testing Of Swine Flu Vaccine Developed Using Novel Technology
• HHS Takes Additional Steps Toward Development Of Vaccine For The Novel Influenza A (H1N1)
• Rituximab Reduces Kidney Inflammation In Patients With Lupus
• Zogenix Initiates Pivotal Phase 3 Clinical Trial For Novel Formulation Of Oral Controlled-Release Hydrocodone
• Baxter Presents Clinical Efficacy Results From Phase III Study Of Seasonal Flu Vaccine
• AmpVacs A Broadly Protective Synthetic Influenza A Vaccine
• Dynavax Selects Clinical Candidate In Universal Flu Vaccine Program
• FDA Recommends H1N1 For Inclusion In Next Year’s Flu Vaccine
• SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN’s Ability To Enhance Response To H1N1 Vaccine
• Targeted Prevention Measures Stopped Spread Of H1N1 Flu At Alabama Boys Camp, Doctor Says
• Walkerton Tragedy: 10 years of water contamination research leads to breakthrough
• Bharat Biotech Begins Phase I Clinical Trials Of HN-VAC – Its Cell Culture H1N1 Vaccine

Tags: damage, erythematosus, kidney, leads, lupus, models, novel, prevention, systemic, vaccine

This entry was posted on Monday, June 15th, 2009 at 3:06 pm and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.